Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANDANTE: PF-04236921 in anti-TNF inadequate responder Crohn's disease
2010-023034-23Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing PF-04236921 dose-ranging with Placebo (2 arms). Primary endpoint: CDAI 70 response rate at Week 8 or Week 12. Started Apr 2011; status: completed.
02
Drugs
pacibekitug
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2010-023034-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023034-23.